Tekmira Gets $5.8M from Hana

Xconomy Seattle — 

Tekmira Pharmaceuticals, the Vancouver, BC-based company with technology to deliver RNA-based therapies in the body, said it has amended a licensing agreement with South San Francisco-based Hana Biosciences. Tekmira has agreed to accept a $5.75 million payment from Hana now, while agreeing to accept lower milestone payments from product candidates later. Tekmira has also agreed to send the $5.75 million to its debt holders to eliminate its debt.